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Sepsis is a major medical problem and massive resources have been invested in developing 
and evaluating alternative treatments. Statistics indicate that sepsis causes between one third and 
one half of all hospital deaths in the United States. Sepsis has a high impact on health care in the 
US, with direct sepsis costs in 2009 exceeding $15.4 billion. A research study found that a 1-hour 
delay in appropriate antimicrobial care resulted in a 7% - 10% rise in mortality. Several professional 
societies seek to reduce sepsis mortality by targeting the timely use of diagnostic tests and 
antimicrobial therapy. The diagnostic instruments available to clinicians to identify the suspected 
pathogen do not make a timely intervention possible. Up to 5 days of incubation are needed for 
blood cultures, the majority of bacteria being detected after 12–48 h. Therefore, fast and simple 
techniques are required for rapid bacterial cell detection and quantification. By using droplet 
microfluidics and a machine learning algorithm, the objective of this study was to propose a 
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technology that analyzes images of bacterial cells by image processing and Support Vector 
Machines algorithm to classify droplets containing the bacteria. The accuracy of the proposed 
technology was 97.2 % for a trained SVM model and with the complete identification and 
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1 INTRODUCTION  
1.1 Sepsis 
Sepsis represents a major medical problem and enormous resources have been invested in the 
development and evaluation of alternative treatments. Sepsis is a complex disorder which occurs as a 
dysregulated reaction to an infection and is correlated with severe failure of organ(s) and a significant risk 
of death. Bacterial infections are one of the causes of sepsis and it is crucially important to detect presence 
of bacteria in patient samples. Sepsis is high incidence and the condition represents one of the leading 
causes of death worldwide. Sepsis is indeed a critical public health concern with large economic 
repercussions. A considerable amount of research and improved clinical procedures have increased the 
speed of sepsis detection and diagnosis over the past 30 years. In 2016, a new definition was developed to 
further refine this process, with a greater focus on organ dysfunction recognition in the context of 
infection(1). In 2017, the WHA and the WHO declared sepsis a global health concern, and adopted a 
resolution to strengthen sepsis prevention, diagnosis and management(2). While sepsis is a global problem, 
most of the available literature and evidence come from high-income countries overwhelmingly. In every 
health care system, there is need for more research and a greater understanding of sepsis, particularly to 
better identify patient populations and personalize treatments. It is also critical that in future, low-income 
and middle-income countries are not ignored by global research and quality-improvement agendas on 
sepsis.  
1.2 Incidence 
In any given country the actual occurrence of sepsis is uncertain. The reported incidence depends 
on the particular term used, the infecting organism, the notification process (such as the use of the 
International Disease Classification 9 coding systems) and the provision of either organ support or 
critical care. Such factors lead to substantial variations between estimates and distinct geographical 
locations. Most of the data documenting the occurrence of sepsis are from high-income countries 
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where sepsis contributes with 2·8 million deaths per year(3). In 2001, Angus and colleagues 
estimated that the frequency of severe sepsis in the United States was more than 750,000 cases per 
year (300 cases per 100,000 population), which is equal to 2.26 cases per 100 hospital 
discharges(4). A reflective analysis of over 2,9 million adults who were admitted to 409 US 
hospitals in 2014, clinical sepsis indicators were found in 6% of hospitalized patients, 21% of 
whom died in hospital or were discharged to hospice. In 35% of all hospitalizations which 
culminated in death, sepsis was present(5). In the United Kingdom, the recorded incidence of 
sepsis in samples originating from ICU is 27% of all ICU admissions, while the frequency in the 
United States is 12%(6). This disparity could be explained in part by the markedly higher number 
of ICU beds available in the United States than in the United Kingdom, and therefore by the 
different triage patterns and admission requirements(7). Generally, the incidence of sepsis is likely 
to be significantly under-reported and with an aging population the incidence will keep rising. 
Perhaps, the true scale of the problem is far higher than what has been published. According to 
statistics, sepsis causes between a third and a half of all hospital deaths in the USA(8). While these 
statistics reflect the incidence of sepsis in high-resource countries, the majority of sepsis deaths 
occur in low-resource countries where it is difficult to accurately determine the exact incidence of 
sepsis. The available evidence indicates that around 90 percent of the world's deaths from chest 
infections occur in low-resource settings(3) and approximately 70 percent of the 9 million deaths 
from neonatal and child chest infections are sepsis-related, and most cases occur in Asia and 
Africa(9). Sepsis can be originated from any infectious organism and consequently, the spectrum 
of syndrome presentations is very wide and varies considerably across geographic regions. Sepsis 
may arise from community settings or may result from a hospital or other health care facility stay; 
furthermore, approximately 80 percent of cases of hospital-treated sepsis arise in the community. 
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The most common infection site contributing to sepsis is the lung (64% of cases), followed by the 
abdomen (20%), bloodstream (15%), and renal and genitourinary tract (14%)(10).  
It is very possible that a baseline mortality from sepsis is simply the nature of the disease itself 
and, despite our best efforts to understand, diagnose and manage the disorder, it is unrealistic to 
expect death rates to drop to zero in reality. Amid enhanced diagnostic procedures and vigorous 
clinical measures, sepsis-related mortality remains high(11). Patients surviving a sepsis episode 
can face prolonged hospital stay and long-term health consequences(12). The effect of sepsis on 
healthcare in the US is high, with the costs directly linked to sepsis exceeding $15.4 billion in 
2009(13). A 1-h delay in adequate antimicrobial therapy results in mortality increases of 7-
10%(14). Inappropriate initial therapy in sepsis patients is associated with a 5-fold reduction in 
survival(15). The Surviving Sepsis campaign, an international collaborative effort by several 
professional societies with the objective of reducing sepsis mortality, aims the timely use of 
diagnostic testing and antimicrobial therapy administration. For a variety of reasons, the diagnostic 
tools available to clinicians to identify the responsible pathogen do not facilitate timely 
intervention(16). Blood cultures (BCs) necessitate up to 5 days of incubation, most bacteria being 
detected after 12–48 h of incubation. Guidelines recommend a minimum of 2 sets of BCs per septic 
episode with at least 40 mL of blood collected in adults but lower blood volume in children and 
neonates. Up to 2 additional BC sets may further optimize BC sensitivity(17). Approximately 40 
to 60% of severe sepsis or shock patients have a microbiologically documented infection. Sepsis 
would remain only clinically suspected in a substantial proportion of patients, increasing the risk 
for a non-infectious cause (i.e. extreme systemic inflammatory response syndrome)(18). Phua and 
colleagues published on a broad retrospective patient cohort study (n = 1,001) with serious sepsis 
ICU admission and compared the characteristics and outcomes of culture-negative versus culture-
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positive episodes. Their results showed that culture-negative patients had shorter hospital stays 
and lower ICU mortality and hospital mortality (35.9% versus 44.0%, P = 0.01) than culture-
positive patients(19). BC's failure to produce a causative organism could be due to a number of 
reasons such as previous antibiotic coverage, which could result in non-viable organisms. While 
guidelines suggest collection of BC before antimicrobial administration, the regularity with which 
this occurs is highly variable, with studies showing that 28%-63% of patients received antibiotics 
before collection of BC(20). False-negative blood may also occur due to the presence of non-
cultivable or fastidious bacteria in the environment of sepsis cultures. Sepsis may also occur due 
to nonbacterial pathogens, such as viral or fungal species. De Prost et al. noted that some patients 
with culture-negative sepsis could have lower levels of procalcitonin and positive viral detection 
in respiratory specimens(18). In addition to false-negative BC, the false-positive BC is also a cause 
of concern. BC may become contaminated during the specimen collection process due to errors. 
Typical contaminants include skin flora such as coagulase-negative staphylococci, α-hemolytic 
streptococci, corynebacterial, and Bacillus species. The negative effect of contaminated BC can 
be substantial, resulting in unnecessary antimicrobial treatment and diagnostic procedures and 
prolonged hospitalization with an average cost of $8,000 - $25,000 per episode. For a negative 
outcome, BC may need up to 5 days of incubation and suffer from limited sensitivity. Usually BC 
bottles are incubated in automated devices that track growth in real time. Positive BC bottles are 
withdrawn from the instrument and gram-stained, and the result is usually communicated as a 
critical value to the clinician, enabling the clinician to narrow down treatment. Laboratories not 
staffed 24/7 may further delay reporting of positive BC due to insufficient staffing. Significant 
increases in mortality (10.1% vs 19.2%) were demonstrated by Barenfanger et al. when positive 
 
 5 
BC Gram stains were delayed by > 1 h(21). Positive Gram stain results must be reported promptly 
but may not always be feasible in small laboratories and community hospitals.  
1.3 Methods to detect and quantify bacteria in Blood Samples 
More recently, laboratories have adopted probe-based multiplex PCR technologies that allow 
bacteria to be quickly identified in positive BC bottles. These panels are able to identify the most 
commonly isolated pathogens within 1–3 h. Such panels can also detect resistance markers such 
as mecA and KPC that would direct treatment choices for a full day or two before results of routine 
susceptibility testing are accessible(22). The use of these panels has been shown to have a huge 
positive impact on patient management, including a decrease in intensive care unit (ICU) stay and 
30-day mortality, although a positive BC is still needed(23).  
For more than 2 decades, molecular diagnostic research has revolutionized the field of clinical 
microbiology. Use of detection strategies for DNA and RNA has served to nearly eliminate the 
role of traditional routine culture for viral pathogens. For instance, cultures for cytomegalovirus 
usually required 21 days of tissue culture incubation, but the results are typically available within 
hours using molecular methods. The implementation of bacterial pathogen detection technologies 
has advanced at a slower pace, in part due to the difficulties of separating typical bacterial flora 
from pathogens. After culture amplification, the role of Nucleic Acid Amplification Tests 
(NAATs) in advancing sepsis detection has been largely limited to identifying pathogens from BC 
bottles. NAAT-based research is promising due to the potential for high sensitivity and the ability 
to detect non-cultivable or non-viable species due to previous antibiotic treatment. One of BC's 
primary limitations is the low circulating organism load (1–10 cfu / mL) during a septic 
episode(24). However, Bacconi et al. determined by using culture methods that 103 or 104 GC 
(genome copies)/mL of bacteria were present in the blood (25). 
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 The first tool approved by the FDA for direct bloodstream detection of a bacterial or fungal 
pathogen was the T2Candida (T2C) assay (T2 Biosystems). Invasive candidiasis remains a 
diagnostic problem for laboratories, with BC being negative in 50% of confirmed and probable 
invasive candidiasis cases(26). There are currently a range of tools available to identify pathogens 
directly from the blood; however, many of these are actually not FDA-approved for use in the US, 
but some have approvals in Europe such as: 
1.3.1 LightCycler SeptiFast 
This system (Roche Molecular System) is an automated platform that can detect 19 
bacterial and fungal pathogens using multiplexed PCR coupled with probe hybridization and DNA 
melt curve analysis using 1.5 mL of whole blood. The pathogen identification is possible in 3.5–5 
hours with subsequent detection of mecA gene associated with methicillin resistance in 
Staphylococcus species. This tool Is capable of carrying out a semi-quantitative analysis which 
may be useful in determining the value of positive results(27). 
1.3.2 MagicPlex Sepsis 
The MagicPlex Sepsis instrument (Seegene) is sensitive enough to detect more than 90 
different bacteria and fungi along with methicillin and vancomycin resistance, by using multiplex 
PCR from 1 mL of whole blood within 3 h. Nevertheless, only a limited subset of the 90 
bacteria/fungi are identified to the species level(24). 
1.3.3 VYOO 
The VYOO Rapid Pathogen Identification System (Analytik Jena Gmbh) uses a 
combination of DNA amplification preceded by an electrophoresis-based analysis to detect 34 
bacteria and 7 fungi using a 5 mL sample volume of whole blood. Moreover, the system also 
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identifies 5 different resistance markers, giving information on methicillin resistance, vancomycin 
resistance, and the existence of at least 2 types of β-lactamases of extended spectrum(24). 
1.3.4 PLEX-ID 
PLEX-ID is a novel technology that incorporates PCR amplification and electrospray 
ionization-mass spectrometry to identify pathogens directly in clinical specimens. This tool could 
detect and identify up to 800 different gram-positive and gram-negative bacteria, fungi and 4 
markers of resistance: mecA, vanA, vanB, and blaKPC. Such markers provide information 
concerning resistance to methicillin, vancomycin, and carbapenem. The method aims the rRNA 
genes and other conserved regions of the bacterial and fungal genomes by using broad-range PCRs 
followed by amplicon analysis by ESI-MS (electrospray ionization mass spectrometry). Pathogen 
detection is enabled by assessing the base composition of the amplified sequences instead of 
evaluating the sequence itself followed by comparing the base composition to a database. The 
system uses 5 mL of whole blood to get a response within 6 hours(24). 
1.3.5 SepsiTest 
SepsiTest (Molzym Molecular Diagnostics) amplifies bacterial 16S rRNA and fungal 18S 
rRNA, allowing more than 345 bacteria and 13 fungi (Sinha) to be identified. This is followed by 
Sanger sequencing and BLAST analysis for identification. The test consists of several steps and 
requires 1 mL of whole blood and can take 8 – 12 hours. The device still fails to detect any 
resistance markers. It can also be used to detect bacteria from other sterile fluids(24). 
1.4 Methods of Quantification in Microbiology 
In the majority of microbiological studies, quantification of bacterial cells is crucial; hence, 
fast and simple techniques are required. The distinction between viable and nonviable micro-
organisms is significant. Within aggregates, viable microorganisms are usually present. 
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Sometimes a mixture of bacteria is counted as a single bacterium by using the normal microbial 
counting system. The term CFU has also been used to denote viable bacteria that are measured by 
calculating the number of observable colonies on an agar-platform. Bacteria are never uniformly 
dispersed in samples; therefore, quantitative outcomes can often be poor, irreproducible, 
particularly in small samples.  
1.5 Culture Based Methods 
Culture-based approaches have been the oldest techniques for identifying microorganisms, 
including pathogenic strains. This approach provides a verified result on the existence of a single 
pathogen. It is observed that the performance rate is high and that these approaches are cost-
effective. However, the biggest drawback in the culture-based method is slow growth, which 
means that excess time is lapsed to produce the final result, which may turn out to be fatal. Growing 
bacteria in liquid medium or agar plates requires long processing times, typically taking up to 18-
24 hours to confirm and quantify growth. It is vital for culture methods to obtain a growth curve 
(OD vs. Time) to determine several time points within the bacterial log phase, which corresponds 
with the linearity of the curve as displayed in figure 1.1a, b. After calculating the dilution factor, 
an aliquot of each time point is collected from the incubated bacterial solution to conduct both 
absorbance measurements and agar plating. The dilution factor is acquired by making several 
dilutions from the original bacterial suspension. Each dilution is plated on agar until a countable 
number of colonies are formed (30 – 300) and each distinct colony represents an individual viable 
bacterial cell. The number of bacteria per mL (CFU) is determined by the total number of colonies 
times total dilution factor per volume of culture plate. Finally, a curve is plotted by using the OD 
measurements and the CFU data based on each time point as shown in figure 1.1 d, e, f. The linear 
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regression of the curve is used to determine the concentration of new bacterial suspensions by 
taking their respective OD measurements. 
 
 
Figure 1.1. Culture Method. a) and d) show the process to obtain bacterial growth curve and c) represents the time points in the 
curve. d) and e) represents the absorbance measurements of the dilutions. f) represents the CFU data from the dilutions.  
1.6 Immunoassays 
Immunoassays are easy to carry out and produce quick results. Moreover, immunoassays are 
usually performed before going directly into a PCR based process. The ELISA is one of the most 
commonly used immunoassays to date. Purity of the antibody plays a crucial role in the 
effectiveness of immunoassays(28). Besides purity, another element influencing the assay is the 
antibody specificity. Polyclonal antibodies have polyvalence (multiple epitopes to bind with). This 
can influence the reaction, resulting in low specificity and sensitivity; therefore, it could potentially 
generate false positive outcomes. The use of several substrates in ELISA has a significant benefit 
 
 10 
as the substrates directly link to the corresponding conjugates and produce coloration that can be 
read by a plate reader. Nonetheless, one of the drawbacks is that antibody interaction is very 
complex and contamination in the intermediate stages can lead to false positive results. In the 
course of time, ELISA methodologies have been changed to suit new experiments. Blocking 
ELISA was developed using E. Coli O157:H7 LPS as antigen. Such modification provides a more 
sensitive result than normal ELISA in the detection of pathogens. Indirect ELISA has been used 
in both cattle serum and human serums to detect anti-O157 antibodies. Nonetheless, due to cross-
reactivity the chances of the outcome being false positive are higher(29). 
1.7 Polymerase Chain Reaction (PCR) Based Methods 
In 1985, Kary Mullis developed PCR, which is one of the seminal discoveries in recombinant 
DNA technology. The concept behind PCR is to amplify and analyze the genes of various 
pathogens; therefore, different primers have been created for each target gene. In general, the main 
advantage of PCR is that the process is rapid and sensitive. In fact, PCR is faster than the culture-
based methods and immunoassays. The amplified product can be obtained as quickly as 30 
minutes, and it has become much easier to differentiate between strains as multiple primer pairs 
are used. PCR has emerged as a very promising method for the detection of pathogen genes; 
however, there are certain drawbacks. Cell lysis, nuclear acid extraction, cross contamination and 
failure to react due to the presence of inhibiting agent or competing DNA from non-target cells are 
some of the difficulties. This can lead to inconsistent outcomes and adversely affect the use of 
PCR in diagnostic applications. PCR methods can not differentiate live from dead cells, therefore 
does not report pathogen viability. The main disadvantage of all PCR detection methods is that 
binding of non-specific double-stranded DNA sequences may generate false positive signals. Thus, 




Biosensors are one of the newest detection platforms, some of which have enhanced 
detection limits that greatly minimize and mitigate the shortcomings of PCR-based techniques(28, 
30). Biosensors used for pathogen detection have three main components: a bio-probe-functional 
sensor platform that gives recognition specificity, a transduction platform that produces a 
measurable signal in the event of target analyte capture, and an amplifier that enhances and 
processes the signal to provide a quantitative estimation of the captured analytes. The key benefit 
of biosensors is that they can detect pathogens with high specificities and sensitivity at low 
detection limits, but biosensors may need extremely sensitive and costly instruments with 
compatible computer software to produce accurate results. 
1.9 Other Detection Methods 
DNA microarray has become important today and has been a useful tool due to its speed, 
sensitivity and specificity. Several pathogens such as B. cereus, E. coli, L. monocytogenes, P. 
aeruginosa, S. enterica, S. aureus, V. parahaemolyticus and, C. freundii were detected by using 
this approach. DNA microarrays can differentiate between bacterial species with high homology. 
For instance, because of the high homology at DNA level, ITS regions of five Bacillus sp. (B. 
anthracis, B. cereus, B. thuringiensis, B. mycoides and B. weihenstephanensis) were difficult to 
differentiate. However, it was possible to detect them by using DNA microarray(31). 
 Ultrafiltration (UF), Immunomagnetic assays (IMS), Immunochromatic assays (ICA), and 
Flow Cytometry (FC) are several of the traditional approaches. Ultrafiltration has been described 
as an efficient procedure for concentrating and recovering microbes from large quantities of water 
and wastewaters. Due to their very small pore sizes, UF membranes can simultaneously 
concentrate viruses, bacteria and parasites on the basis of size exclusion. The UF-based technique 
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included hollow-fiber UF as the primary stage for microbes concentration and then membrane 
filtration for bacterial culture assays (32). Conventional IMS technique uses an external source to 
catch magnetic particles against the side of the test tube resulting in poor results due to high 
background microflora(33). ICA has been a useful, quick, easy, highly sensitive, specific method 
and does not require expensive equipment or reagents; however, its success is highly dependent 
on the specificity of the antibodies. FC is a responsive analytical technique which can quickly track 
bacterial physical conditions. High sample size and precision, measurement of thousands of cells 
per second, and the possibility of cell sorting are the principal advantages of flow cytometry. 
However, this approach is expensive and because these instruments are sophisticated, especially 
the laser-based cell sorter, skilled operators are usually required to obtain optimum or at least 
acceptable performance(34). 
1.10 Microfluidic Devices as a Potential Platform for Detection and Quantification of 
Bacteria 
Microfluidics has shown tremendous potential in developing biotechnology applications by 
using small sample sizes, fast reaction times, parallelization and sample-relevant manipulation of 
fluids(35). By proving an effective performance of a wide range of functions in biotechnology 
laboratories, including sequencing of DNA and RNA, antimicrobial resistance screening, and drug 
discovery, microfluidic systems have revolutionized the experimental biology and biomedical 
research methods(36). Droplet microfluidics has enabled high-performance, highly parallel 
microfluidic assays which can generate millions of data points for a specific sample/assay. 
Analysis of big data, especially large numbers of images, needs intense computational resources, 
advanced image processing techniques, and high-throughput analysis methods such as machine 
learning. Machine learning is a subfield of Artificial Intelligence (AI) that enables computers to 
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learn without explicit programming. In this study, we propose a technology that analyzes images 
of individual microdroplets generated by a microfluidic platform and classify droplets containing 
bacterial cells as full and the rest of the droplets as empty by using image processing and machine 
learning algorithms. This technology can be used to quantify bacteria concentration within a fluid 
sample for a number of applications in clinical diagnostics, microbiology, and food industry. In 
chapter 2, we explain that the probability of encapsulation of a given number of cells in droplets 
is calculated by the Poisson distribution, where  is the number of cells in a droplet and  is the 
average number of cells per droplet volume. The original concentration of the bacterial suspension 
had to be obtained using culture methods (see figure 1.2 a, b, c) as well as the average droplet 
volume of the total droplets produced by the microfluidic device (see figure 1.2 d, e, f, g). As a 
result, both results were used to determine the  value. In chapter 3, we describe our algorithm, 
which was named Intensive-based Algorithm (IBA), to classify droplets by using major axis 
length, perimeter, and circularity droplet properties (see figure 1.2 d, e, h). We selected a squared 
region around the centroid of each droplet, to calculate the mean and median of pixel intensity. As 
a consequence, IBA classified efficiently full and empty droplets. In addition, a model was trained 





Figure 1.2. Schematic Diagram. a) and b) represent the culture method process to obtain bacterial suspension concentration. c) 
and d) display droplet microfluidic process. e) represents the averaged droplet size to calculate averaged droplet volume. f) and 
g) show the two classification methods.  
2 MICROFLUIDICS 
2.1 Droplet Microfluidics 
Microfluidics is the field of study in which micrometer-scale network of channels, reservoirs 
and valves are utilized to drive and manipulate fluids. It emerged in the early 1990s from 
microanalytical methods and microelectronic circuits. Novel microfluidic fluid handling 
techniques have been developed with applications in the medical and biotechnology fields as well 
as in materials science and chemistry. Microfluidics has contributed significantly to the expansion 
of microbial ecology by enabling scientists to study the activities of microbes in highly controlled 
microenvironments. Droplet-based microfluidics is a subfield of microfluidics where an aqueous 
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phase is segmented into individual droplets within an immiscible carrier fluid (generally mineral 
or fluorinated oil) to encapsulate cells, organic molecules and reagents. Cell encapsulation 
provides significant benefits for microenvironmental control and sample processing. Microfluidic 
systems provide an ideal platform for cell encapsulation as the droplet size is typically comparable 
to that of cells. The most common technique of encapsulating cells uses microfluidic channel 
geometries that combine co-flowing water and oil phases, where the water phase is dispersed into 
the oil phase and breaks into discrete water droplets. Using the common geometries such as T-
junctions, flow-focusing or co-flowing intersections (see Figure 2.1), the formation of droplets can 
be precisely regulated by adjusting the differential volumetric flow rates of the immiscible fluid 
phases(37). 
 
Figure 2.1. Microfluidic geometries for droplet generation. 
Methods of cell encapsulation use either passively or actively formed droplets. Passive droplet 
generation takes place through the use of an external pressure sources such as syringe and pressure- 
driven pumps. On the other hand, active droplet production occurs with the application of an active, 
short-duration pressure source. Figure 2.2 shows a typical example of passive encapsulation where 




Figure 2.2. Passive cell encapsulation 
Because the number of cells per droplet can have a substantial effect on the viability of a particular 
process, it is highly desirable to have a control measurement. For instance, the apparent reaction 
kinetics may double when two cells rather than one are encapsulated in a droplet(37). In situations 
where encapsulated cells are both abundant and considerably smaller than droplets (e.g. with 
encapsulated micron-sized bacteria), the number of cells per droplet can fairly be presumed to be 
indicative of the volumetric concentration of cells(38). When cells are randomly distributed in an 
aqueous solution, Poisson statistics determine the number of cells per encapsulated volume. In the 
case of suspended cells moving through microfluidic channels, the spatial distribution and 
therefore the timing of their arrival at the droplet forming site is essentially random for passive 
encapsulation. If cells are randomly entering the water-oil interface, the average cell arrival rate is 
known, and the arrival of individual cells occurs independently of other cells; then the probability 




  (2.1) 
 
 17 
where  is the number of cells in a droplet and  is the average number of cells per droplet volume. 
Additionally, Collins et al. (2015) defined  as the ratio between the volume fraction of cells in 




(2.2), where the average cell and droplet volume 𝑉𝑐 and 𝑉𝑑  are constant for given oil-water flow 
rates and channel geometry. Hence,  can be described as  = 
𝜙𝑠
𝜙𝑑
 (2.3), where cellular volumetric 
fraction 𝜙𝑠 ≪ 1 (𝑖. 𝑒.  cells are sparsely distributed),  𝜙𝑠 = 
𝑄𝑐
𝑄𝑓
 (2.4), and 𝑄𝑐 , 𝑄𝑓  are the time-
averaged volumetric flow rate of the cells and fluid rate for water (37).  can be adjusted to control 
the probability of encapsulating a specific number of cells within droplets (figure 2.3 and table 
2.1). For instance, if =0.05, 95.13% of droplets will contain no cells (empty droplets), 4.76% of 
droplets will contain only one cell and 0.12% of droplets will have more than a single cell. When 
=0.5, 60.66% of droplets will be empty, 30.33% of droplets would contain one cell and 7.59% of 
droplets would have two cells. If =1, 36.79% of droplets will be empty, 36.79% of droplets would 
contain one cell, and 18.4% of droplets would contain two cells. When =2, 27% of droplets can 




Figure 2.3. Poisson distribution, p (𝜅 ,), provides the probability of encapsulating a given number of cells (𝜅) within single 
droplets for a given cell concentration,  (0.05, 0.5, 1, 2).  
 
 
Table 2.1. Probability p (𝜅, ) of encapsulating a number of cells (𝜅) for various discrete values of average cell concentration, . 
Figure 2.4 shows us that when 𝜅 = 0, 𝑝(𝜅, 𝜆) displays an exponential decay, meaning that when 
 value increases the probability of getting an empty droplet decreases, that is, more droplets would 
contain cells. If  = 0, more than 95% of the droplets are empty and when   = 1, 37% of the 
droplets would not contain any cell;  = 2, 13% of the total number of droplets are empty;  = 3, 
approximately 6% of the total number of droplets would not contain cells. When 𝜅 = 1,  and  = 
1, 37% of the total number of droplets would contain one cell;  = 2, 27% of the total number of 
droplets would contain a single cell;  = 3, approximately 13% of the droplets would contain one 
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cell. When 𝜅 = 2, and  = 1, 18% of the total number of droplets would contain two cells;  = 2, 
27% of the total number of droplets would contain two cells;  = 3, approximately 23% of the cells 
would contain two cells. Therefore, as the  value increases, the probability distribution shifts 
right, indicating that the likelihood of droplets containing one or more cells is higher when  value 
is increased. 
 
Figure 2.4. Poisson distribution p (,κ) with four discrete values of κ (0, 1, 2, 3) against several values of . 
Droplet microfluidics has grown significantly, mainly thanks to the implementation of an easily 
accessible manufacturing technique, soft lithography, to fabricate microdevices using patterned 
elastomeric polymers(39). Research and development on single cell analysis involving 
microfluidic techniques has significantly increased over the last decade(40-42). Microfluidic 
systems offer small volumes of reagents, dynamic reagent control, high-throughput, 
biocompatibility and high sensitivity, which helped these systems to emerge as an important 
enabling technology platform for the study of single cells. Microfluidics have several applications 
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in single-cell research, such as PCR, isolation and culturing of cells, cytotoxicity, sorting, 
separation, clone formation, lysis, gene and protein expression, and antibody secretion studies. 
Most of the microfluidic systems used for analyzing single-cell behavior require spatial separation 
or compartmentalization of cells in surface arrays or in two-phase systems, such as droplets(43). 
Cell assays normally require multiple steps, such as compartmentalization, manipulation, and 
measurement. Droplet microfluidics can integrate these steps and increase the throughput. Using 
an inert carrier fluid, commonly oil, microfluidic devices can compartmentalize reactants by 
encapsulating aqueous reagents in micron-sized droplets. These devices can generate 
monodispersed droplets with a volume range of 0,05 pL to 1 nL or approximately 5 µm to 120 µm 
in diameter(44). Small volumes conserve costly reagents, and high speeds greatly reduce the time 
taken to evaluate extremely large libraries. Different materials could also be used to generate 
picolitre-sized compartments, but an inert oil-water interface has the advantage of protecting 
droplet contents from the microfluidic device walls. Accordingly, droplets eliminate fouling and 
cross contamination, and multiple applications exemplify these advantages(45). Droplet 
microfluidics can also often produce higher speeds by allowing the detection of reactions after 
shorter time periods. If a single molecule or cell is present in a volume of 1 mL, its concentration 
is extremely low. If that volume of 1 mL is emulsified into one million droplets, each 1 nL in 
volume, one of these droplets may contain the single molecule or cell, and its concentration in the 
droplet will increase by one million. As reaction rates rise with effective concentration, reaction 
times which are normally on the order of hours in bulk can decrease to seconds or minutes within 
droplets (46, 47). Therefore, the minimum concentration of reaction products needed for detection 
will be more rapidly achieved in smaller volumes. Cells, DNA, and other particles or molecules in 
the aqueous phase can be encapsulated within droplets. In fact, molecules, cells and particles can 
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be encapsulated separately in individual droplets(48, 49). Microfluidic techniques can be merged 
to conduct almost any biological reaction or experiment that can be performed on a traditional 
microtiter well plate. Several of the most widely used assays in biological research have already 
been demonstrated in microfluidic droplets. Small volumes, high speeds, low noise, and isolation 
of droplet contents from solid surfaces and fluidic control are main reasons for using droplets 
instead of well plates (45).  
2.2 Droplet Microfluidics for Microbial Studies 
Micro/nanotechnology and bacteriology may seem like two different worlds. Nevertheless, 
the interaction between these two disciplines has developed a complex and quickly growing area 
of research over the years. Several micro/nanotools have been developed to probe individual 
bacteria and multi-species communities in diverse but very well-defined environments (35, 50). 
Along with a number of exciting new technologies, the convergence of micro/nanotechnology and 
bacteriology has given rise to new biological perspectives that would have been inaccessible 
without these disciplines merged. Comprehending how bacteria assemble and function is a great 
challenge, requiring an interdisciplinary approach. Typical sizes of a bacterial cell (0.5-3 µm) 
correlate well with the length scales where micro and nanotechnology can shape and manipulate 
the environment. Conventional methods for cultivating bacteria are incompatible with long-term 
monitoring of an individual cell or the careful manipulation of its microenvironment. Microfluidics 
and nanofabrication can develop well-defined chip ecosystems to research population-level 
processes that replicate the sophistication of the natural environment(51).  Droplets microfluidics 
has the capability of generating, manipulating and monitoring droplets, which carry single cells or 
small populations of bacteria. Therefore, these abilities open new approaches for solving problems 
in diagnostics and for research on bacterial evolution. Effectively, droplet microfluidics emerged 
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as one of the technological innovations that has provided new microbiological experimental 
alternatives such as detecting and identifying pathogens, antibiotic susceptibility testing, microbial 
physiology research, and biotechnological applications. Using droplets to study microorganisms 
has several advantages over classical techniques such as bioreactors, flasks, Petri dishes and multi-
well plates. The stochastic confinement of microorganisms in droplets, which is the process to 
separate the whole sample into many small volumes so that the number of droplets exceeds the 
number of cells, has the most significant advantage(52). The second most important aspect of 
droplet microfluidics is the prospect of massively analyzing large numbers (even millions) of 
individual droplets. The third most significant advantage is capability of carrying out more 
complex experimental protocols involving iterative operations on droplets(50).  
2.3 Methods 
Microfluidic technology was applied to process a fluid sample containing bacteria with the aim of 
encapsulating single bacterial cells within picoliter sized droplets. Equation 2.1 allow us to calculate the 
theorical  value considering the desired number of bacterial cells in each droplet (k value). By determining 
the original concentration of the suspension through culture methods, we can dilute the bacterial solution 
based on the theorical  value and obtain the required bacterial concentration for encapsulation.  After 
calculating the total number of droplets generated (full and empty droplet) as well as the averaged volume 
of the droplets, we can estimate the concentration of the original bacterial suspension. In this study, we 
determine the  value by using the original bacterial suspension concentration based on culture methods 
and the averaged droplet volume. 
2.3.1 Microfluidic chip fabrication 
Microfluidic biochips were manufactured in PDMS using standard soft lithography 
procedures. SU-8 master molds with relief patterns of microchannels and flow-focusing geometry 
were manufactured using photolithography on silicon wafers. The preparation of the substrate was 
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conducted by cleaning the wafer with acetone and isopropyl on both sides 3-4 times and by drying 
with air gun. The wafer was aligned on the spin coater and SU-8 was poured over the wafer. After 
spinning at 3000 rpm for 30 seconds, a soft bake was performed at 65oC for 3 minutes and at 95oC 
for 9 minutes. Once the wafer cools down at room temperature, a UV exposure step was conducted 
at 215mJ/cm2 for 12.8 seconds. Post exposure bake was done at 65oC for 2 minutes and at 95oC 
for 7 minutes. The wafer was immersed, swirled and agitated in a developer solution (1,2-
Propanediol mono-methyl ether acetate). After the master mold was silanized, PDMS was casted 
over the master mold and baked at 75oC for 2 hours. Inlet and outlet holes were punched in the 
PDMS.  The PDMS slab is then peeled of the mold, and a microfluidic device is formed by bonding 
it to a 75 x 50 x 1,2 mm glass microscope slide, using oxygen plasma for 60 seconds(53). 
2.3.2 Microfluidic Experiments 
All tubing, tools and syringes were sterilized with 70% (v/v) ethanol and all 
solutions/mediums were autoclaved prior to use. The bacteria suspension and the oil were loaded 
into gastight syringes with 27-gauge needles and infused into the device by using syringe pumps. 
One pump injected bacteria solution through the inlet hole and the other pump injected oil through 
two different holes. A fluorinated oil (Ethoxy fluorinated methyl alkane) from BIO-RAD was used 
as the carrier phase for droplet generation.  In order to harvest the droplets, the outlet tubing was 
connected to a plastic vial. The filled vial was incubated and shaken at 37oC at 150 rpm for 8 hours 
for bacterial growth. 
2.3.3 Bacterial cell culture 
Cells were obtained from ATCC [ E. Coli strain K-12 W3110 ATCC # 25923 (MSSA)]. 
Stock solutions of the bacterial cells were prepared by using Luria-Bertani (LB) medium Miller 
formulation (BD, Sparks, MD) containing 10% (v/v) glycerol and stored at -80oC. A frozen stock 
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vial was brought to room temperature for each experiment, streaked onto an agar plate and 
incubated overnight at 37oC. Single colonies from the plates were picked and transferred to LB 
medium and grown in a shaker incubator at 37oC and 225 rpm for 4 hours until it reaches an OD600 
of 1.0. OD measurements were performed by using Synergy H1 Hybrid Multi-Mode Microplate 
Reader from Biotek Instruments. Then, cell density was adjusted to desired concentration by 
diluting in LB prior to droplet encapsulation experiments. All procedures were performed in close 
proximity to a Bunsen burner flame to maintain sterility, and all tubing, devices, flasks, syringes 
and solutions used were either autoclaved or sterilized by EtOH 70% (v/v). 
2.4 Results and Discussion 
2.4.1 Bacterial Growth Curve 
The relationship between time and number of cells is not linear but exponential during the 
log phase; nevertheless, the growth curve is frequently plotted on a semilogarithmic graph, which 
means the values on the y axis are logarithmic and gives us the impression of a linear relationship. 
Once, the linear relationship is identified, we used several time points within the log phase to make 
dilutions and obtain their respective CFU on agar plate with the objective of plotting OD 
measurements versus cell concentration. Thus, this graph can be used to determine cell 
concentration of a bacterial suspension based on OD measurements.  After culturing bacterial cells 
in 5ml of LB, a diluted solution was prepared (10X). A 20 L of the diluted bacterial suspension 
was taken and mixed with 180L of LB. 18 of such aliquots (200L of sample per well) were 
prepared in a 96-well plate. 129 absorbances were measured on the microplate reader at 600nm, 
at 37oC, and double orbital shaking. The optical density measurements were obtained every 6.5 
minutes for 16 hours. Unfortunately, this experiment was done once, and reproducibility 




Figure 2.5. Optical density vs time measurements. Purple plot represents natural logarithm of OD’s vs time and green plot 
represents OD values vs time. 
The E. Coli growth curve is shown in figure 2.5. Bacterial cultures grow exponentially and the 
growth rate is a change in the number of cells per minute, which is estimated as a change in OD 
per minute(54). Here, since bacterial suspension was only diluted 10x, the lag phase was not 
detected. It was necessary to obtain both plots in order to determine linearity in the log phase. As 
a result, we determined that the bacterial growth was linear for OD values between OD = 0.1 and 
OD = 0.6.  
Colony Forming Units (CFU) was determined by performing serial dilutions of the cell 
suspension. After diluting the bacterial solution 107x, a 100l of the suspension was spread on to 
an LB agar plate and incubated overnight at 37oC. This procedure was conducted twice for each 
time point as well as optical density measurements at 50 min, 75 min, 100 min, 125 min, 150 min 




Figure 2.6. Optical density vs time (min) measurements to determine CFU in a cell suspension diluted 107 times. 
After counting colonies, the CFU was calculated for each time point and plotted against their OD 
values respectively. As a result, the linear regression equation is given as: 
𝑦 = 2.0959 ∗ 10−11 ∗ 𝑥 + 0.1421         (2.5) 
The below figure shows a fairly strong relationship (r2 = 0.9777) between the optical density 
measurements and the bacterial cell concentration.  
 
Figure 2.7. Correlation between bacterial cell concentration (bacteria cells/ml) and optical density 
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2.4.2 Bacteria Encapsulation in Droplets 
The microfluidic device was designed with a flow focusing geometry (see figure 2.1b). As 
displayed in figure 2.8, the biochip contains three inlets, a main channel for injection of the 
bacterial suspension, two inlet channels for the fluorinated oil injection, and one outlet channel.  
 
Figure 2.8. Droplet microfluidic setup. 
The depth of channels is 50 m, the top and bottom channels are 100 m wide. The width of the 
middle channel is 60 m (see figure 2.9).  
 
Figure 2.9. Microfluidic droplet device design. 
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The bacterial solution was segmented into droplets by the shear flow of carrier fluorinated oil (see 
figure 2.10). Droplets were produced using the flow rates 30 L/h and 90 L/h for aqueous and 
oil phase, respectively. Droplets were collected into an Eppendorf tube for 1h and incubated in a 
shaker incubator at 37oC and 150 rpm for 4 hours and the droplets containing the bacteria are 
imaged by a microscope (See Section 3.6). 
 
Figure 2.10. Droplet generation by using device design from figure 2.9. 
3 MACHINE LEARNING 
3.1 Background 
In 1950s, the field of artificial intelligence (AI) began when a number of pioneers from the 
new field of computer science posed the question if machines can "think". A descriptive field 
definition of artificial intelligence is as follows: an attempt to automate human intellectual work. 
AI is a broad discipline that involves machine learning and deep learning. For quite a long time, 
many experts believed that artificial intelligence at the human level could be achieved by having 
programmers design a sufficiently large set of explicit rules for the manipulation of knowledge. 
This approach is known as symbolic AI and from the 1950s until the end of the 1980s, it was the 
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dominant model for AI. For machine learning, human data and the predicted responses to the data 
come from the rules. Such rules can then be used to produce original answers for new data. Several 
examples are given to a task; and in these examples, it finds a mathematical framework that 
essentially helps the system to establish rules for the automation of the task. This combination of 
mathematics and computer science is motivated by the particular computational challenges in 
constructing mathematical models from large data sets that can contain billions or trillions of data 
points. The learning types used by computers can be categorized into two groups: supervised 
learning and non-supervised learning. 
3.2 Supervised Learning 
Supervised learning begins with the objective of predicting a known output or target. It is 
about mapping data to known targets, given a set of examples. Supervised learning emphasizes on 
classification, which includes selecting among subsets to best describe a new instance of data and 
predicting an unknown parameter(55). Some of the most important supervised learning algorithms 
are k-Nearest Neighbors, Linear Regression, Logistic Regression, SVMs, Decision Trees and 
Random Forests, and Neural Networks. The pattern recognition method uses Deep Neural 
Networks (DNNs), which can help interpret medical tests, electrocardiograms, and vitals, and 
recognize images from pathology specimens, retina, endoscopy, and skin lesions. The analysis of 
a neural net is typically compared to the evaluation of medical professionals using a plot of true-
positive against false-positive values, called Receiver Operating Characteristics (ROC), where the 
region under a curve (AUC) is used to demonstrate the accuracy level(56). In a study using a broad 
training dataset of nearly 130,000 digitized dermascopic images, at least 21 US board certified 
dermatologists were matched in output by an algorithm that had an AUC of 0.96 specifically for 
carcinoma and 0.94 specifically for melanoma(57). Another study involved a group of 58 
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international dermatologists to measure the accuracy of melanoma skin cancer diagnosis with a 
Convolutional Neural Network (CNN); the mean ROCs were 0.79 versus 0.86, respectively, 
suggesting an increased algorithm efficiency compared to with health professionals (58). In a 
whole-slide imaging (WSI) analysis of breast cancer, with or without metastasis of the lymph node, 
which compared the output of 11 pathologists to that of various algorithmic interpretations, the 
findings differed and were partly affected by the length of time the pathologists had to analyze the 
slides. Some of the five algorithms did better than the team of pathologists, who had different 
expertise. The pathologists obtained 129 test slides and had less than 1 minute per slide 
examination, which is definitely not representative of usual workflow(59). 
3.3 Unsupervised Learning 
In comparison, there are no results that can be expected in unsupervised learning. Instead, 
we seek to find patterns or groups within the data that occur naturally. It is basically a more difficult 
task, and the importance of unsupervised learning in such groups is also assessed by its success in 
subsequent supervised learning tasks. Some of the most important unsupervised learning 
algorithms are k-Means, Principal Component Analysis (PCA), Expectation Maximization, 
Hierarchical Cluster Analysis (HCA), and kernel PCA(55). From a technical point of view, while 
supervised learning mainly addresses classification and regression problems, unsupervised 
learning tackles more clustering and reduced dimensionality. Patterns identified in unsupervised 
learning commonly need to be assessed for utility either by human interrogation or through 
application within a supervised learning task. Clustering refers to defining groups within data, 
supplying data to an algorithm, analyzing them and finding any implicit correlation within the data 
that can be categorized into sub-sections and patterns within the data to be identified. Because of 
the nature of the data and the heterogeneity of medical patients, intuition can make it difficult to 
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classify groups, and the ability to elucidate such groups enables targeted diagnosis. Vranas et al. 
analyzed a large data collection from an intensive care unit, where resource burden and outcomes 
prediction were considerable challenges. Through evaluating patient variables retrospectively 
using an unsupervised algorithm (clustering), they were able to classify patient subgroups with 
substantially different clinical courses even with identical diagnoses, and by applying the 
predictive clusters to a separate, unknown data set, the predictive power persisted(60). 
3.4 Principle Machine Learning Algorithms for Medicine  
3.4.1 Support Vector Machine 
Support Vector Machine (SVM) is a supervised learning algorithm designed to divide data 
into two or more categories. The term 'support vector' essentially refers to the margin used by the 
algorithm to assess whether or not data is part of the group (see figure 3.1). Researchers often refer 
to the use of 'kernels' in SVM, which are mathematical tools that modify data in certain ways to 
make data more easily separated into categories(61). Although this is simple for two and three-
dimensional data sets, the power of the SVM is that it can be used for complex data sets with many 
variables or dimensions. Because of its versatility, SVM has been implemented to a myriad of data 
types, from the classification of presence/absence of micro-calcifications in breast mammograms, 




Figure 3.1. Separation of two-dimensional data by Support Vector Machines 
3.4.2 Neural Networks 
Neural networks, also known as artificial NN, try to use multiple computation layers to 
simulate the idea of how human brain interprets and draw conclusions from data. NNs are primarily 
mathematical models designed to manage complex and diverse information; the nomenclature of 
this algorithm is derived from the use of "nodes," similar to brain synapses (see figure 3.1). An 
NN's learning process may either be supervised or unsupervised. The neural net is set up to learn 
in a supervised manner if the desired output is already targeted and implemented to the network 
by training data, while the unsupervised NN does not have such pre-identified target outputs and 
the aim is to group similar units close together within a certain value range. The NN is used for 
medical diagnostic purposes for both regular and variable data sets as well as data sets using 




Figure 3.2. Artificial Neural Network 
3.4.3 Deep Learning 
Deep learning is a particular machine learning subfield: a modern perspective on data 
learning representations that emphasizes learning successive layers of progressively meaningful 
representations. The difference between deep learning and a simple neural network is that the 
number of node layers is increased, and the total size of the network is greater, allowing for more 
accurate representation of complex interrelationships. To explain this, Convolutional Neural 
Network (CNN), a form of feedforward NN designed to imitate neural processes within the brain, 
is often applied to image processing tasks. CNNs are the cornerstone of all image-based deep 
learning (see figure 3.2). The architecture allows nodes to connect to a part of the input image. 
Convolutional blocks work within an image by moving along an image through a small window 
area and generating the weighted sum of the pixel values for the filter in the region and applying 
a non-linear transformation. Such convolutional layers are merged with pooling (subsampling) 
layers, retrieving the most dominant values in the feature maps and reducing their resolution. The 
loop is replicated several times until a particular resolution size of the filter map is obtained. In 
essence, the early phases of the pipeline are programmed to resolve spatial data and convolutions 
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serve as special feature detectors (e.g. edges, lines), ultimately teaching the network to connect 
adjacent pixels in space. The result of these layers is a low-dimensional embedded representation 
of an image which provides a much better representation of the image content than other methods 
of feature-extraction(65, 66). A recent medical example of deep learning is the implementation of 
a deep learning algorithm by Gulshan et al. to detect diabetic retinopathy from retinal fundus 
images. Researchers took 128,175 retinal images that had already been studied by 
ophthalmologists as their training set, built a deep learning algorithm that could analyze new 
images and recognize diabetic retinopathy with 97.5 percent sensitivity and 93.4 percent 
specificity(67). 
 
Figure 3.3. Convolutional Neural Network 
3.5 Methods 
3.5.1 Data acquisition 
Once the droplets were generated, a solution with two layers consisting of emulsion and 
oil was collected into an Eppendorf tube at the outlet of the biochip. The Eppendorf tube, which 
contains droplets with bacterial cells, was incubated for 4 hours at 150 rpm to allow bacterial cells 
grow insight the droplets. Hence, this incubation allowed us to produce full droplets and obtain 
droplet images to distinguish full and empty droplets. Then, 30 L of the upper layer, which 
contains the emulsion with water-in-oil droplets, were taken and injected into a microfluidic flow 
cell. The flow cell was made of two glass slides, sandwiched with two pieces of double-sided tape 
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placed at the edges to form a capillary channel. Then, images of the microfluidic flow cell were 
obtained by using an optical microscope (Nikon Eclipse Ti2) coupled with a CCD camera (Basler 
acA1920-155um).  
3.5.2 Data Analysis 
Images were segmented by using ImageJ and Image Segmenter MATLAB App to analyze 
the average droplet size and perform the initial classification steps. We have developed a 
MATLAB script which inputs each image and classifies droplets containing bacteria as opposed 
to empty droplets. For machine learning analysis, we used the Statistics and Machine Learning 
Toolbox from MATLAB. 
3.6 Results and Discussion 
3.6.1 Image Analysis for Droplet Size 
Images were acquired by using 6x phase contrast objective lens. To segment the images 
for droplet size analysis, the Triangle algorithm of Image J was chosen to perform thresholding to 
divide each image into two or more-pixel classes. Based on the camera specifications, the pixel 
size (H x V) is 5.86 m; therefore, the distance in pixels was set at 0.9767 pixels/m. The average 
area of the droplets was approximately 3400 m2; thus, we calculated the average diameter of the 
droplets to be 65.5 m. 
3.6.2 Measure Bacteria Biomass with Poisson Distribution 
When encapsulating bacteria cells into droplets, the cell number distribution in droplets 
follows Poisson statistics. Equation 2.1 estimates the fraction of droplets containing  number of 
bacteria cells, with a given mean bacterial concentration for per droplet volume (). In this work, 
a bacterial suspension was prepared, and optical density measurements were taken four times 
which have an average of 𝑂𝐷̅̅ ̅̅  = 1.045. Replacing this value in equation 2.5, the approximate 
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concentration of the bacterial suspension (C) would be 4.3079 x 1010 cells/mL. Equation 2.1 
defined  as the average number of cells per droplet volume; therefore, we can deduce  = C ∗
𝑉𝑑  (2.6), where C can be defined as the number of bacteria cells per mL and 𝑉𝑑  as the average 
of droplet volume. By using the average diameter of the droplets,  𝑉𝑑   value would be 1.47 x 10
-7 
mL. Hence, the value of  for this experiment would be 6333.14, which would represent the 
average number of cells per droplet for this study. These results rely on measuring the initial 
bacteria concentration through a combination of OD600 and CFU measurements and tend to 
overestimate the initial concentration of bacteria in the original sample. While a  value as high as 
6333.14 warrants all droplets containing bacteria, the experimental data suggests otherwise (see 
Section 3.6.3 below), confirming that the original bacteria concentration is overestimated by 
conventional methods. 
3.6.3 Image Segmentation for Droplet Classification 
Images were segmented by using the adaptive threshold algorithm of MATLAB App and 
closed masks were created with a morphology shape- disk with a radius of 3. Also, droplets that 
















Figure 3.4 a) and b) are images obtained as a result of the experiments. Left images show full droplets, which are those with the 
contrasting circles in their inner background. Conversely, empty droplets are those circles whose inner background is black. The 
right images are the corresponding segmentation of the left images. 
3.6.4 Image Classification by IBA 
After segmentation, statistical analysis of the droplets was performed based on major axis 
length, circularity, and perimeter properties to identify the centroids of the droplets.  As shown in 
figure 3.5, we assumed that values lower than 20 pixels and greater than 80 pixels of the major 
axis lengths could be considered noise. However, we observed fewer artefacts with centroids and 




Figure 3.5. Histogram: Major Axis Length of Droplets 
The circularity value for a perfect circle is 1; therefore, we could remove all the values greater than 
1.0. We could see in figure 3.6 that most of the values were between 0.9 and 1.0. Nevertheless, we 
were able to identify more droplets with centroids between 0.7 and 1.0. 
 
Figure 3.6. Histogram: Circularity of Droplets 
Analyzing the histogram of the perimeter values as displayed in figure 3.7, we observed that the 




Figure 3.7. Histogram: Perimeter of droplets 
When we applied all these properties as exclusion criteria, we could identify >97% of the centroids 
of the droplets. Furthermore, we set a square of 20 pixels (H x V) around each centroid in order to 
determine the mean and the median of intensity of the pixels of each square. As shown in figure 
3.8, full droplets are displayed with yellow squares and empty droplets with blue squares. 
 
Figure 3.8. Droplet Classification of figure 3.4a. Yellow squares represent full droplets and blue squares represent empty droplets. 
As a result, the total number of droplets identified by the algorithm was 352, 164 of which 
corresponded to full droplets (47 %) and 188 empty droplets (53 %). 
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3.6.5 Image Classification by Support Vector Machines 
In addition to the previous algorithm, we used Support Vector Machines to classify full 
droplets and empty droplets.  As we had a low dimensional dataset, we chose fitcsvm, which is the 
Train Support Vector Machine classifier used for binary classification. 338 cropped droplet images 
were obtained from figure 3.4b and a squared area (20 pixels x 20 pixels) around the centroid of 
each droplet was used to create our model.  The size of the training and test dataset was 320 and 
18, respectively. Figure 3.9 shows the confusion matrix for our trained model when we used the 
test dataset and all the 18 images were classified 100% correctly.  
 
Figure 3.9. Confusion matrix to evaluate training of SVMs for droplets of figure 3.4b. 
 
After training, we used our model to classify 356 cropped squared images (20 pixels x 20 pixels) 
from figure 3.4a, which contains 191 empty droplets and 165 full droplets. As displayed in figure 
3.10, 187 droplets were correctly classified as empty droplet and 6 empty droplets were 
misclassified as full droplets. This corresponds to 52.4 % and 1.7 %, respectively, of all 356 
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droplets. Furthermore, the model classified 159 droplets correctly as full and misclassified 4 full 
droplets as empty. This corresponds to 44.7 % and 1.1 %, respectively, of the total number of 
droplets. Out of 193 empty droplet predictions, 96.9 % were correct and 3.1 % were incorrect. 
Additionally, out of 163 full droplet predictions, 97.5 % were correct and 2.5 % were incorrect. 
Hence, out of 191 empty droplets, 97.9 % were correctly predicted as empty and 2.1 % were 
predicted as full. Out of 165 full droplet cases, 96.4 % were correctly predicted as full and 3.6 % 
were classified as empty. Overall, 97.2 % of the predictions were correct and 2.8 % were incorrect. 
 
 
Figure 3.10. Confusion matrix to evaluate binary classification accuracy of SVMs for droplets of figure 3.4a. 
4 CONCLUSIONS AND FUTURE WORK 
In this work, we have proposed a technology based on microfluidics and machine learning to 
quantify the bacteria in a liquid sample. Our platform breaks the sample into tiny picoliter droplets 
while encapsulating bacteria within the sample, cultures the bacteria within the emulsion using 
conventional incubation techniques, allowing the bacteria to populate the droplet, then classifies 
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the droplets that contain bacteria as full and those that do not contain bacteria as empty droplets. 
As a result, we obtain a quantitative population-level representation of the emulsified bacterial 
colonies, following Poisson statistics, which allows us to accurately estimate the initial bacterial 
concentration in the original sample. In order to accomplish our goal, we conducted experiments 
that allowed us to determine the original concentration of the bacterial suspension to calculate  
value, which is the average number of bacterial cells per droplet. In chapter 2, we described the 
validated methods and protocols that we used to obtain the concentration of the bacterial solution. 
In chapter 3, we described the image processing methods as well as the machine learning 
algorithms (supervised model based on support vector machines) to classify full and empty 
droplets. Our results showed that our proposed algorithm (IBA) identified and classified full and 
empty droplets correctly based on a dataset acquired from droplet images provided in figure 3.4 
and 3.5. By using the same dataset, our trained SVM model correctly classified 97.2% of the 
images and only 2.8 % of the images was classified incorrectly. 
 Unfortunately, reproducibility for the culture method could not be evaluated; therefore, the  
value of the bacterial suspension could be lower than the calculated  value for this study. It is also 
possible that the number of full and empty droplets could have been different if reproducibility 
experiments for droplet microfluidics had been conducted. Even if we would have the 
reproducibility evaluation, it is likely that the culture method could be still overestimating the  
value as compared to that of Poisson distribution. These limitations can be overcome in the future 
by conducting three or five experiments to assess reproducibility for both the culture method and 
the droplet microfluidics. 
Nevertheless, these findings have provided valuable information to propose further research 
in quantitative microbiology. For instance, a new model in machine learning can be trained by 
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using images of incubated droplets at 50 min, 75 min, 100 min, 125 min, and 150 min to classify 
full and empty droplets through Convolutional Neural Network algorithm. By doing this research, 
we could improve speed and accuracy for bacterial quantification and detection. Another future 
study could evaluate the performance of our proposed model with droplets containing different 
concentration of bacteria cells along with different types of bacteria by using deep learning 
algorithm. Therefore, this research describes the fundamental principles of a technology that offers 
a versatile tool to detect and quantify bacterial cells in biomedical fields where rapid and accurate 
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